Table 3.
Odds ratios of baseline clinical factors for use of SGLT2i or GLP-1RA
| Variable | SGLT2i |
GLP-1RA |
||
|---|---|---|---|---|
| Odds ratio | Adjusted odds ratio | Odds ratio | Adjusted odds ratio | |
| Age ≥65 years | 1.05 (0.84‒1.31) | - | 1.05 (0.51‒2.16) | - |
| Female sex | 0.57 (0.45‒0.72) | 0.64 (0.48‒0.86) | 1.39 (0.70‒2.76) | - |
| BMI ≥25 kg/m2 | 1.54 (1.25‒1.91) | 1.67 (1.29‒2.17) | 1.63 (0.83‒3.21) | - |
| Diabetes duration, yr | ||||
| <10 | Reference | Reference | Reference | Reference |
| 10–19 | 0.91 (0.69‒1.19) | 1.03 (0.76‒1.41) | 2.72 (1.00‒7.41) | 2.31 (0.84‒6.36) |
| ≥20 | 0.51 (0.38‒0.69) | 0.85 (0.60‒1.21) | 4.24 (1.64‒10.93) | 3.24 (1.21‒8.68) |
| Insulin use | 0.57 (0.42‒0.78) | 0.58 (0.40‒0.84) | 3.12 (1.55‒6.28) | 1.37 (0.64‒2.94) |
| HbA1c ≥7% | 1.97 (1.58‒2.45) | 2.59 (1.94‒3.45) | 6.17 (2.16‒17.60) | 5.58 (1.66‒18.80) |
| eGFR <60 mL/min/1.73 m2 | 0.39 (0.31‒0.50) | 0.37 (0.26‒0.51) | 0.68 (0.32‒1.46) | - |
Values are presented as odds ratio (95% confidence interval).
SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1RA, glucagon-like peptide 1 receptor agonist; BMI, body mass index; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular filtration rate.